loading page

Perturbations in spike specific peripheral T follicular helper cells in SARS-CoV2 breakthrough convalescent individuals immunized by BBV152 vaccine.
  • +4
  • Soumya Sengupta,
  • Shubham Shaw K,
  • Sanchari Chatterjee,
  • Gargee Bhattacharya,
  • Prakash Barik K,
  • Soma Chattopadhyay,
  • Satish Devadas
Soumya Sengupta
Institute of Life Sciences
Author Profile
Shubham Shaw K
Institute of Life Sciences
Author Profile
Sanchari Chatterjee
Institute of Life Sciences
Author Profile
Gargee Bhattacharya
Institute of Life Sciences
Author Profile
Prakash Barik K
Institute of Life Sciences
Author Profile
Soma Chattopadhyay
Institute of Life Sciences
Author Profile
Satish Devadas
Institute of Life Sciences

Corresponding Author:[email protected]

Author Profile

Abstract

SARS-CoV2 infection has caused an increase in mortality and morbidity but with vaccination, the disease severity has significantly reduced. But with emergence of various variants of concerns (VOCs), the vaccine breakthrough infection has also increased. Here, we studied circulating spike specific T follicular response (cTfh) in infection naïve vaccinees and convalescent vaccinees (individuals who got delta breakthrough infection after 2 doses of BBV152 vaccine) to understand their response as they are the most crucial cells that are involve in vaccine mediated protection by helping in B-cell maturation. Our results indicated that cTfh cells in both the groups recognized wild type and delta spike protein but memory response to wild type spike was superior in infection naïve than in convalescent group. The cytokine response particularly IL-21 from cTfh cells was also higher in infection naïve than convalescent vaccines indicating a dampened cTfh response in convalescent vaccines after breakthrough infection. Also, there was positive correlation between IL-21 from cTfh cells and neutralizing antibodies of infection naïve vaccinees. Multiple cytokine analysis also revealed higher inflammation in convalescent vaccinees. Our data indicated necessity of third booster dose may be individual specific depending in the steady state functional phenotype of immune cells.
31 May 2023Submitted to Journal of Medical Virology
01 Jun 2023Submission Checks Completed
01 Jun 2023Assigned to Editor
01 Jun 2023Review(s) Completed, Editorial Evaluation Pending
09 Jun 2023Reviewer(s) Assigned
22 Jun 2023Editorial Decision: Revise Major
22 Jul 20231st Revision Received
24 Jul 2023Submission Checks Completed
24 Jul 2023Assigned to Editor
24 Jul 2023Review(s) Completed, Editorial Evaluation Pending
28 Jul 2023Reviewer(s) Assigned
14 Aug 2023Editorial Decision: Accept